While Spravato (esketamine) and ketamine are chemically related glutamate receptor modulators, key differences in their FDA approval status, administration methods, and insurance coverage make them distinct treatment options for severe depression.
Spravato: FDA-approved specifically for Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD) with acute suicidal ideation.
Ketamine: FDA-approved as an anesthetic, but used off-label when prescribed for depression, anxiety, or PTSD.
Spravato: Administered as an intranasal spray self-administered under medical supervision in an approved clinical setting.
Ketamine: Typically delivered via intramuscular (IM) injection, allowing for direct bioavailability.
Spravato: Formulated using only the S-enantiomer (esketamine), an isolated, highly potent mirror-image molecule of ketamine.
Ketamine: Contains a racemic mixture (a 50/50 blend of both R- and S-enantiomers).
Spravato: Uses lower, standardized dosing protocols (56mg or 84mg), often resulting in milder or more predictable transient side effects.
Ketamine: Dosing is customized by body weight and can be adjusted dynamically during an infusion.
Both Spravato and IV ketamine offer rapid-acting relief for patients who haven’t found success with traditional antidepressants. Consulting a qualified psychiatric clinician is the first step toward building an individualized treatment plan tailored to your medical history, budget, and mental health goals.
